Search for a biotechnology company is unusual in that the total addressable audience may be a few thousand people worldwide, each capable of authorising a very large purchase. Volume based keyword planning misleads badly here, because the queries that matter carry small numbers and the ones with impressive volume are searched by students and job seekers.
Scientists search like specialists
They search assay names, catalogue numbers, protocols, target and pathway names, instrument models and troubleshooting problems, often in shorthand. Those queries are low volume and high intent. Pages that answer them precisely, with real protocol detail and data, are what earn the visit and the citation, and generic category pages are not.
Technical documentation is the marketing
Protocols, application notes, validation data, compatibility tables and troubleshooting guides are read by the people who specify, and gating them costs you the specification. Publish them openly and gate the commercial material instead. This is the single most commonly inverted decision in the sector.
Regulatory and claim constraints
Research use only labelling, claims about clinical or diagnostic applications, and anything implying a therapeutic outcome are constrained by the product's regulatory status. The web copy is promotional material and is read as such, so the claim review that applies to a brochure applies to the page.
Measuring a small audience
Track named accounts, document downloads, quote requests and citations of your material in published work rather than sessions. A quarter that produced two enquiries from target institutions may be an excellent quarter, and a traffic chart will describe it as a poor one.
Questions people ask about biotech seo
Is search worth it with such low volumes?
Yes, because the value per conversion is very high and the competition for precise technical queries is thin. It is judged on which accounts arrived rather than on how many.
Should technical documents be gated?
Generally not. Gating specification material loses the designs and protocols you would have been written into, which is worth far more than the contact record.
Who should write biotech content?
Scientists, or writers working directly from scientists. In this audience inaccuracy is detected immediately and costs credibility that is slow to rebuild.